The advantages and disadvantages of various C treatment modalities approved by guidelines are discussed by experts. infection caused by clostridium difficile.

Published Date: 09 Aug 2023

An infectious diseases expert and a gastroenterologist discuss the advantages and disadvantages of various treatment modalities for Clostridioides difficile infection (CDI) in a brand-new Annals "Beyond the Guidelines" feature. The .

Read Full News

Latest News

Pancreatic Cysts: What’s the Actual Cancer Risk?

Pancreatic cysts are common and usually considered low risk — but even those lesions signal a significantly elevated and sustained cancer risk.

UTI Treatment Shift: Is Nitrofurantoin Coming Out on Top?

A large Spanish trial reports higher cure rates with 5-day nitrofurantoin therapy than with fosfomycin or pivmecillinam in women with uncomplicated UTIs.

Takeda Engaged in Antitrust Scheme to Delay Generic Constipation Drug, US Jury Finds

A U.S. jury on Monday found Takeda Pharmaceutical liable for causing about $885 million in damages by delaying a generic version of its constipation drug Amitiza through an...

Blood Proteins Link Poor Sleep to Increased Cancer Risk

Suboptimal sleep health, reflected in low sleep proteomic scores, is consistently associated with an increased risk for cancer, particularly gastrointestinal malignancies.

Housing Instability Tied to Lower Rates of CRC Screening

Unmet health-related social needs, especially housing instability and transportation barriers, are linked to lower rates of screening for colorectal cancer among US adults.

Olanzapine Cuts Radiation-Induced Nausea

The drug, widely used for chemotherapy-related nausea, may also be highly effective for symptoms caused by abdominal-pelvic radiotherapy.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Todays Updates

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

Latest News

Pancreatic cysts are common and usually considered low risk — but even those lesions signal a significantly elevated and sustained cancer risk.

A large Spanish trial reports higher cure rates with 5-day nitrofurantoin therapy than with fosfomycin or pivmecillinam in women with uncomplicated UTIs.

A U.S. jury on Monday found Takeda Pharmaceutical liable for causing about $885 million in damages by delaying a generic version of its constipation drug Amitiza through an...

Suboptimal sleep health, reflected in low sleep proteomic scores, is consistently associated with an increased risk for cancer, particularly gastrointestinal malignancies.

Unmet health-related social needs, especially housing instability and transportation barriers, are linked to lower rates of screening for colorectal cancer among US adults.

The drug, widely used for chemotherapy-related nausea, may also be highly effective for symptoms caused by abdominal-pelvic radiotherapy.

News All Time

Clinical Pearls to Advance Multidisciplinary Team-Based Care for Patients With GEP-NETs

Clinical Pearls to Advance Multidisciplinary Team-Based Care for Patients With GEP-NETs

Navigating the Future of Upper GI Cancer Treatment: Mechanisms, Personalization, and Expert Insights

Navigating the Future of Upper GI Cancer Treatment: Mechanisms, Personalization, and Expert Insights

Checkpoint, Claudin, and Beyond: Optimizing Biomarker-Driven Decisions in Advanced/Metastatic G/GEJ Cancer Care

Checkpoint, Claudin, and Beyond: Optimizing Biomarker-Driven Decisions in Advanced/Metastatic G/GEJ Cancer Care

EASL: European Association for the Study of the Liver

ACG: American College of Gastroenterology

AASLD: American Association for the Study of Liver Diseases

AASLD Video Pearls: Video Pearls from the American Association for the Study of Liver Diseases

CCC: Crohn's & Colitis Congress

Multiple Drugs Flagged for Higher C. Diff Risk

Increased risks observed for analgesics and corticosteroids, among others, in Swedish study

Dulaglutide or Tirzepatide? Worldwide Biopharma Changes

Also in TTHealthWatch: how treatments for hepatitis C have been used

Raw Dairy Farm Recalls Cheese Products as FDA Investigates E. Coli Outbreak

The company initially refused to recall the products

Is Surveillance Colonoscopy Needed for Elderly Patients With Adenomas?

Study finds deaths from other causes far surpass colorectal cancer diagnosis, death

Gaslighting in Gastro Care; Antidepressants and IBS Mortality; Diverticulitis Season

News and commentary from the world of gastroenterology and hepatology

Is Kissing for Celiacs Gluten-Free? Study Weighs In

Small trial finds little in the way of gluten transfer when celiac and non-celiac partners kiss

Strategy Reduces Inappropriate Proton Pump Inhibitor Use

Patient- and physician-facing interventions together doubled the reductions in PPI use

1.8 Billion MASLD Cases; Improving HCC Surveillance; Ultrasound for Crohn's Disease

News and commentary from the world of gastroenterology and hepatology

Recommended News For You

Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL

Innovative oncology therapeutics are being created in collaboration between Moderna and Immatics.

Researchers Challenge USPSTF's Lung Cancer Screening Criteria

Pancreatic Cancer: A Novel CD40 Agonist-Chemo Combo Shows Promise.

For older LBCL patients, Axi-Cel exhibits durable responses and extends overall survival.

A study on lung cancer provides additional proof of the value of screening.

Experts Debate AQUILA Trial Findings in Smoldering Multiple Myeloma

Recommended Articles For You

Harnessing Cuproptosis: A Novel Nanomedicine Strategy for Triple-Negative Breast Cancer 

Neoepitope Vaccines in Oncology: Precision, Sequencing, and Immunotherapy Frontiers 

A Comprehensive Guide to Using an ABG Calculator for Accurate Diagnosis 

Cancer-Keeper Genes: Novel Therapeutic Targets for Disrupting Tumor Maintenance 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca

2.

More Support for Early Detection; Cancer in Men Rising; Diet Drives Colon Cancer

3.

Asymptomatic Brain Metastases in EGFR-Mutant NSCLC

4.

Mapping lifelong chronic health risks for childhood cancer survivors

5.

Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC

1.

Respiratory Ramifications of Systemic Disease: A Comprehensive Review

2.

Revolutionizing Lung Cancer Treatment: Exploring the Benefits of Wedge Resection Surgery

3.

Trends in Incidence, Care, and Surgery for Medullary Thyroid Cancer: A Review

4.

Cancer Care Advances: Metformin, Digital Tools, and Artificial Renal Support

5.

Molecular Mechanisms, Clinical Efficacy, and Stem Cell Therapy Integration in Leukemia Treatment

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions

2.

First Line Combination Therapy- The Overall Survival Data in NSCLC Patients

3.

Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC

4.

A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II

5.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part III

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot